Mario Schlosser Sells 395,000 Shares of Oscar Health (NYSE:OSCR) Stock

Oscar Health, Inc. (NYSE:OSCR) insider Mario Schlosser sold 395,000 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $18.43, for a total transaction of $7,279,850.00. Following the completion of the transaction, the insider directly owned 501,148 shares of the company’s stock, valued at approximately $9,236,157.64. The trade was a 44.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Oscar Health Trading Down 2.3%

NYSE OSCR opened at $18.01 on Friday. The firm has a 50 day simple moving average of $16.46 and a 200-day simple moving average of $15.33. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.86 and a current ratio of 0.86. Oscar Health, Inc. has a one year low of $11.20 and a one year high of $22.78. The firm has a market cap of $4.66 billion, a price-to-earnings ratio of -22.24 and a beta of 1.87.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.01. Oscar Health had a negative net margin of 1.50% and a negative return on equity of 13.78%. The business had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter last year, the firm posted $0.20 earnings per share. The business’s revenue for the quarter was up 29.0% compared to the same quarter last year. Equities research analysts anticipate that Oscar Health, Inc. will post 0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OSCR has been the subject of a number of recent research reports. Wells Fargo & Company lowered Oscar Health from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $16.00 to $10.00 in a report on Friday, July 11th. Wall Street Zen cut Oscar Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Piper Sandler decreased their price objective on Oscar Health from $14.00 to $13.00 and set a “neutral” rating for the company in a research note on Thursday, August 14th. Baird R W cut Oscar Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 25th. Finally, Raymond James Financial cut Oscar Health from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 24th. Four research analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Sell” and an average price target of $12.07.

Institutional Investors Weigh In On Oscar Health

Several institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its stake in Oscar Health by 285.6% during the second quarter. Osaic Holdings Inc. now owns 186,997 shares of the company’s stock worth $4,009,000 after purchasing an additional 138,505 shares during the last quarter. Straightline Group LLC lifted its stake in Oscar Health by 3.7% during the second quarter. Straightline Group LLC now owns 18,082 shares of the company’s stock worth $388,000 after purchasing an additional 640 shares during the last quarter. Marex Group plc purchased a new stake in Oscar Health during the second quarter worth approximately $266,000. State of Wyoming lifted its stake in Oscar Health by 564.7% during the second quarter. State of Wyoming now owns 112,146 shares of the company’s stock worth $2,404,000 after purchasing an additional 95,274 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new stake in Oscar Health during the second quarter worth approximately $64,000. Hedge funds and other institutional investors own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.